54 related articles for article (PubMed ID: 24468132)
1. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
[TBL] [Abstract][Full Text] [Related]
2. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
[TBL] [Abstract][Full Text] [Related]
3. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM; Mai EK; Hanafiah NH; Shi CX; Zhu YX; Bruins L; Barrio S; Jedlowski P; Merz M; Xu J; Stewart RA; Andrulis M; Jauch A; Hillengass J; Goldschmidt H; Bergsagel PL; Braggio E; Stewart AK; Raab MS
Blood; 2016 Sep; 128(9):1226-33. PubMed ID: 27458004
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review.
Padhi S; Varghese RG; Ramdas A
Indian J Med Paediatr Oncol; 2013 Oct; 34(4):283-91. PubMed ID: 24604959
[TBL] [Abstract][Full Text] [Related]
6. Utility of Cyclin D1 in the Diagnostic Workup of Hematopoietic Neoplasms: What Can Cyclin D1 Do for Us?
Wang W; Medeiros LJ
Adv Anat Pathol; 2019 Sep; 26(5):281-291. PubMed ID: 31261248
[TBL] [Abstract][Full Text] [Related]
7. CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells.
Xie B; Zhao L; Zhang Z; Zhou C; Tian Y; Kang Y; Chen J; Wei H; Li L
BMC Cancer; 2023 Oct; 23(1):955. PubMed ID: 37814227
[TBL] [Abstract][Full Text] [Related]
8. Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined
Malik M; Maqbool M; Nisar T; Akhter T; Ujan JA; Algarni AS; Joufi FAA; Alanazi SSK; Almotared MH; Bekhit MMS; Jamil M
Oncol Res; 2023; 31(6):899-916. PubMed ID: 37744271
[TBL] [Abstract][Full Text] [Related]
9. Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma.
Niazi Y; Paramasivam N; Blocka J; Kumar A; Huhn S; Schlesner M; Weinhold N; Sijmons R; De Jong M; Durie B; Goldschmidt H; Hemminki K; Försti A
Cells; 2022 Dec; 12(1):. PubMed ID: 36611892
[TBL] [Abstract][Full Text] [Related]
10. Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness.
Jung SH; Park SS; Lim JY; Sohn SY; Kim NY; Kim D; Lee SH; Chung YJ; Min CK
Exp Mol Med; 2022 Nov; 54(11):1967-1978. PubMed ID: 36380017
[TBL] [Abstract][Full Text] [Related]
11. Degradation strategy of cyclin D1 in cancer cells and the potential clinical application.
Chen S; Li L
Front Oncol; 2022; 12():949688. PubMed ID: 36059670
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.
Jiang Y; Zhang C; Lu L; Wang X; Liu H; Jiang Y; Hong L; Chen Y; Huang H; Guo D
Technol Cancer Res Treat; 2022; 21():15330338211065252. PubMed ID: 35098809
[No Abstract] [Full Text] [Related]
13. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of
Deng C; Si C; Ye X; Zhou Q; Zeng T; Huang Z; Huang W; Zhu P; Zhong Q; Wu Z; Zhu H; Lin Q; Zhang W; Fu L; Zheng Y; Qian T
J Cancer; 2021; 12(7):1936-1944. PubMed ID: 33753991
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.
Bloedjes TA; de Wilde G; Guikema JEJ
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494394
[TBL] [Abstract][Full Text] [Related]
16. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.
Mulcrone PL; Edwards SKE; Petrusca DN; Haneline LS; Delgado-Calle J; Roodman GD
Sci Rep; 2020 Oct; 10(1):17319. PubMed ID: 33057033
[TBL] [Abstract][Full Text] [Related]
17. Multiple Myeloma: Available Therapies and Causes of Drug Resistance.
Pinto V; Bergantim R; Caires HR; Seca H; Guimarães JE; Vasconcelos MH
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050631
[TBL] [Abstract][Full Text] [Related]
18. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer.
Costea T; Vlad OC; Miclea LC; Ganea C; Szöllősi J; Mocanu MM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936346
[TBL] [Abstract][Full Text] [Related]
19. High expression of CHML predicts poor prognosis of multiple myeloma.
Zhang W; Cao L; Liu X; He X; Zhang Y; Yang Z; Yang P; Wang J; Hu K; Zhang X; Liu W; Yuan X; Jing H
J Cancer; 2019; 10(24):6048-6056. PubMed ID: 31762814
[TBL] [Abstract][Full Text] [Related]
20. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.
Gonzalez-McQuire S; Dimopoulos MA; Weisel K; Bouwmeester W; Hájek R; Campioni M; Bennison C; Xu W; Pantiri K; Hensen M; Terpos E; Knop S
MDM Policy Pract; 2019; 4(1):2381468318814253. PubMed ID: 30729167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
